Read this with care. A per-patient cost is not a measure of efficiency. It rises with
survival — a country whose patients live longer accrues more follow-up, more lines of therapy
and more end-of-life care per person, so a high figure can mark better outcomes rather than
worse value. It also depends on how long each study followed its patients, which varies from one
year to a lifetime. And it counts only CRC care: the cost of treating unrelated conditions during
years of life gained is excluded, as it is in almost all cost-of-illness work. There is deliberately
no total, per-capita or %GDP view here — multiplying these figures by a population would mix
cost concepts. Use the annual cost map for that.
Anchor study
No study
Sources. One anchor study per country and cost type, taken from the Commission's
extraction sheet and restricted to figures that measure the cost of a newly diagnosed patient —
a first year, an initial phase, a treatment course or a lifetime. Conversions: value ÷ World Bank
annual-average market FX (PA.NUS.FCRF) or PPP factor (PA.NUS.PPP) for the study's price year,
× US CPI-U to 2026 (CPI 2026 = 334.4). Every anchor, its alternates and its caveats are listed
in CRC_map_anchor_signoff.xlsx.